Odonkor, M.R. Dodurgali, F.R. Cox, I.J. Klimov, and A. Abd-Elsayed in the journal Nutrients, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may alleviate chronic pain by interacting with the gut microbiome and the gut-brain axis. The study examines how microbial metabolites, spinal microglia, and dietary signaling intersect with pain sensitization pathways.
Gut Microbiota and GLP-1 Signaling in Chronic Pain
According to the review, chronic pain is linked to dysregulation of the gut-brain axis and alterations in the gut microbiome. Researchers searched databases including Embase, Web of Science, and PubMed through June 2026, identifying 825 initial records and ultimately drawing on 97 references to evaluate how gastrointestinal signals affect nociception. Fermentable fiber intake and microbial metabolites, such as short-chain fatty acids (SCFAs), stimulate enteroendocrine L cells to secrete GLP-1, which regulates metabolic, immune, and gastrointestinal functions.
Did you know? GLP-1 receptors are expressed directly in astrocytes, microglia, and neurons across brain regions involved in pain signaling and metabolic control.
Cellular Mechanisms and Preclinical Findings
According to the published findings, GLP-1 receptor expression is upregulated in spinal microglia following peripheral nerve injury and during inflammation. GLP-1R activation promotes interleukin-10 (IL-10) expression and beta-endorphin signaling while suppressing inflammatory pathways like the NLRP3 inflammasome. In preclinical experiments cited in the review, intrathecal GLP-1 receptor agonists alleviated nerve injury-, formalin-, bone cancer-, and diabetes-induced hypersensitivity by 60% to 90% without altering acute nociceptive responses.
Clinical Evidence Across Pain Phenotypes
Clinical data show mixed results across specific conditions. According to the 68-week STEP 9 trial involving 407 individuals, 2.4 mg of semaglutide therapy improved osteoarthritis pain scores by nearly 42 points compared to 28 points for the placebo group, alongside greater weight loss and reduced analgesic medication use. However, a separate randomized trial of 156 participants found that liraglutide produced modest weight loss but did not improve knee pain, leaving the relative contribution of weight loss versus direct analgesia uncertain. Additional clinical evaluations noted reduced headache days in patients with idiopathic intracranial hypertension and pain reductions in irritable bowel syndrome patients treated with the GLP-1 analog ROSE-010.
Frequently Asked Questions
What are GLP-1 receptor agonists?
GLP-1 receptor agonists are medications primarily developed to treat type 2 diabetes and obesity by mimicking the glucagon-like peptide-1 hormone.
How do GLP-1 RAs affect chronic pain?
According to the Nutrients review, GLP-1 RAs may reduce pain sensitivity by enriching short-chain fatty acid-producing gut microbes, suppressing spinal inflammation, and interacting with gut-brain axis signaling pathways.
Have human clinical trials confirmed these analgesic effects?
While trials like STEP 9 showed improvements in osteoarthritis pain scores and other studies noted benefits for headaches, authors caution that the evidence base remains heterogeneous and no human study has yet confirmed that microbiome changes causally mediate analgesia.
If you found this analysis insightful, consider subscribing to our newsletter for the latest updates on medical research and gut-brain axis studies.
Worth a look